Cargando…

Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients

BACKGROUND: Currently, mismatch repair-deficient (dMMR) status is a promising candidate for targeted immune checkpoint inhibition therapy in colorectal cancer (CRC) patients, however, the potential immunological mechanism has not yet been well clarified and some other predictors need to be excavated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shou-Sheng, Yang, Yuan-Zhong, Jiang, Chang, Quan, Qi, Xie, Qian-Kun, Wang, Xiao-Pai, He, Wen-Zhuo, Rong, Yu-Ming, Chen, Ping, Yang, Qiong, Yang, Lin, Zhang, Bei, Xia, Xiao-Jun, Kong, Peng-Fei, Xia, Liang-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045865/ https://www.ncbi.nlm.nih.gov/pubmed/30005666 http://dx.doi.org/10.1186/s12967-018-1570-z

Ejemplares similares

Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer
por: Liu, Shousheng, et al.
Publicado: (2019)

Immunoscore in mismatch repair‐proficient and ‐deficient colon cancer
por: Wirta, Erkki‐Ville, et al.
Publicado: (2017)

Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells
por: Schwarz, V A, et al.
Publicado: (2002)

Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer
por: Swan, Rebecca, et al.
Publicado: (2016)

Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer
por: Yang, Lin, et al.
Publicado: (2017)

Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells
por: Nehmé, A, et al.
Publicado: (1999)

Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers
por: Hale, Vanessa L., et al.
Publicado: (2018)

Robust Glycogene-Based Prognostic Signature for Proficient Mismatch Repair Colorectal Adenocarcinoma
por: Li, Yixi, et al.
Publicado: (2021)

Using amide proton transfer-weighted MRI to non-invasively differentiate mismatch repair deficient and proficient tumors in endometrioid endometrial adenocarcinoma
por: Li, Yuan, et al.
Publicado: (2021)

Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value
por: He, Wen-Zhuo, et al.
Publicado: (2018)

Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort
por: Zwart, Koen, et al.
Publicado: (2023)

IGSF6 is a novel biomarker to evaluate immune infiltration in mismatch repair-proficient colorectal cancer
por: Rong, Yu-ming, et al.
Publicado: (2023)

Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers
por: Li, Jinming, et al.
Publicado: (2023)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer
por: Jimenez-Rodriguez, Rosa M., et al.
Publicado: (2020)

Risk for Hereditary Neoplastic Syndromes in Women with Mismatch Repair-Proficient Endometrial Cancer
por: dos Santos, Jennifer Thalita Targino, et al.
Publicado: (2023)

Gut microbiota distinct between colorectal cancers with deficient and proficient mismatch repair: A study of 230 CRC patients
por: Jin, Min, et al.
Publicado: (2022)

Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer
por: Zhang, Cong-Min, et al.
Publicado: (2016)

ASO Author Reflections: Clinical Outcome After Upfront Curative-Intent Local Treatment of Metastases in Patient with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer
por: Zwart, Koen, et al.
Publicado: (2023)

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
por: Antill, Yoland, et al.
Publicado: (2021)

Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer
por: Ramchander, Neal C., et al.
Publicado: (2020)

Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer
por: Eppenberger, Manuela, et al.
Publicado: (2010)

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022)

Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma
por: Giacomelli, Mauro, et al.
Publicado: (2023)

Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes
por: Kim, Jin K., et al.
Publicado: (2022)

Efficient engineering of chromosomal ribosome binding site libraries in mismatch repair proficient Escherichia coli
por: Oesterle, Sabine, et al.
Publicado: (2017)

Mismatch repair deficiency in ovarian cancer
por: Fuh, Katherine
Publicado: (2022)

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2023)

Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance
por: Chen, Kuo-Hsing, et al.
Publicado: (2016)

Association between Mismatch-repair Genetic variation and the Risk of Multiple Primary Cancers: A Meta-Analysis
por: Kong, Pengfei, et al.
Publicado: (2017)

Complete remission of alpha-fetoprotein-producing gastric cancer by combined tislelizumab-apatinib treatment of a patient with proficient mismatch repair: a case report
por: Xiang, Jinyu, et al.
Publicado: (2022)

Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report
por: Chen, Mengni, et al.
Publicado: (2019)

Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance
por: Liao, Xiyi, et al.
Publicado: (2017)

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
por: Zheng, Zhiwei, et al.
Publicado: (2022)

Biallelic Mismatch Repair Deficiency in an Adolescent Female
por: Hildreth, Amber, et al.
Publicado: (2018)

Assessment of mismatch repair deficiency in ovarian cancer
por: Crosbie, Emma J, et al.
Publicado: (2021)

Genetic Characteristics of Mismatch Repair-deficient Glioblastoma
por: KAWAGUCHI, Kei, et al.
Publicado: (2021)

Unexplained mismatch repair deficiency: Case closed
por: Eikenboom, Ellis L., et al.
Publicado: (2022)

Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer
por: Zhou, Guoying, et al.
Publicado: (2018)

Dendritic cell paucity in mismatch repair–proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy
por: Ho, William W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8k376nq6unka2ccnlf6brp31h3